Inactive Instrument

Press Releases Emergent Biosolutions Inc CINNOBER BOAT

Equities

0IGA

US29089Q1058

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Emergent BioSolutions Continues Driving Progress Against the Opioid Epidemic & Recognizes National Naloxone Awareness Day	Jun. 06	GL
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 23, 2024	May. 10	GL
Emergent Biosolutions: Q1 Earnings Snapshot	May. 01	AQ
Emergent BioSolutions Reports First Quarter 2024 Financial Results	May. 01	GL
Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position	May. 01	GL
Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone	May. 01	GL
Emergent BioSolutions Announces Amendment to its Existing Credit Facility	Apr. 30	GL
Emergent BioSolutions to Release First Quarter 2024 Financial Results and Conduct Conference Call on May 1, 2024	Apr. 23	AQ
Emergent BioSolutions to Release First Quarter 2024 Financial Results & Conduct Conference Call on May 1, 2024	Apr. 22	GL
Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis	Mar. 28	GL
Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility	Mar. 25	GL
Emergent Biosolutions: Q4 Earnings Snapshot	Mar. 06	AQ
Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results	Mar. 06	GL
Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024	Feb. 29	GL
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO	Feb. 21	GL
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO	Feb. 21	AQ
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense	Jan. 11	GL
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense	Jan. 11	AQ
Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024	Jan. 09	GL
Emergent Biosolutions: Q3 Earnings Snapshot	Dec. 11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Emergent Biosolutions Inc CINNOBER BOAT

Equities

0IGA

US29089Q1058

Press Releases

Filters